Disodium NADH:Exports & Compliance White Paper 2026

I. Executive Summary

Beta-nicotinamide adenine dinucleotide, reduced form, disodium salt (CAS 606-68-8) is the reduced pyridine coenzyme NADH as its disodium salt, supplied as research-, diagnostic- and bioprocess-grade material. It is the 1,4-dihydronicotinamide form of NAD+, carrying the hydride equivalent that oxidoreductases transfer to their acceptors. The material is supplied for laboratory, analytical and bioprocess applications only. It has no approved therapeutic indication as supplied, it is not a finished consumer or dietary product, and no anti-aging, energy-metabolism or NAD+-booster claim is made for it.

The 2026 sourcing environment is defined by a split market. High-volume research demand from reagent formulators competes for the same enzymatic reduction capacity as smaller campaigns requiring low endotoxin and DNase/RNase-free handling. Buyers who specify only HPLC purity routinely receive material that fails on the parameter governing performance: the NADH-to-NAD+ ratio at the moment of use. Oxidation between release and use, not synthesis impurity, is the dominant failure mode.

This paper reviews the route classes now used industrially, the specification set separating a functional coenzyme from a degraded one, the regulatory perimeter across the European Union, the United States, China and Japan, and the cold-chain discipline needed to deliver the reduced form intact. It also sets out what professional buyers should require: a validated 340 nm enzymatic assay, a real stability database, defensible change control and a quality system scaled to the declared end use.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

NADH disodium salt, C21H27N7Na2O14P2 and relative molecular mass near 709.4, is a dinucleotide of nicotinamide riboside joined by a pyrophosphate bridge to adenosine 5'-monophosphate. The reduced ring absorbs near 340 nm with a molar extinction coefficient around 6220 M-1 cm-1, whereas oxidised NAD+ does not contribute at that wavelength. This single spectroscopic difference underpins both purity determination and its role as a consumable 340 nm chromophore.

• Hydride transfer chemistry and redox potential: The couple acts as a two-electron, one-proton transfer agent: dehydrogenases deliver the 4-position hydride to the acceptor and regenerate NAD+. With a standard redox potential near -0.32 V the reaction is reversible and becomes product-favourable only when coupled to a driving or removing reaction, which forces cofactor regeneration rather than stoichiometric use.
• Stability window and degradation pathways: Degradation is strongly pH dependent. Below roughly pH 6 the reduced ring is destroyed by acid-catalysed hydration and loss of the nicotinamide function; above roughly pH 10, base-catalysed adduct formation gives species retaining absorbance but no activity. The practical window lies around pH 7.0 to 9.0. Both forms are light-sensitive and oxidised by dissolved oxygen, a reaction catalysed by trace copper and iron.

2.2 Synthesis and Manufacturing Technologies

No manufacturer assembles the dinucleotide de novo at commercial scale. Routes converge on producing oxidised NAD+ first, by fermentation or by enzymatic assembly from nicotinamide mononucleotide and adenosine nucleotides, followed by one controlled reduction and salt-form adjustment. Competition therefore centres on the reduction method, control of sodium stoichiometry, and the downstream operations separating intact NADH from its oxidation and degradation products.

• Enzymatic reduction with coupled regeneration: Formate dehydrogenase, classically from Candida boidinii, with formate is the dominant industrial choice because the only coproduct is carbon dioxide, which self-removes and drives the equilibrium. Alternatives use secondary alcohol dehydrogenase with isopropanol, glucose dehydrogenase, or phosphite dehydrogenase. The reaction runs under nitrogen, is stopped by ultrafiltration, and the product is captured directly on anion exchanger.
• Chemical and electrochemical reduction with polishing: Sodium dithionite remains the low-capital route; it is fast but generates sulfite residues, mixed reduced isomers and inactive adducts that inflate apparent 340 nm content, demanding preparative chromatography. Electrocatalytic reduction and ruthenium or rhodium transfer hydrogenation have reached pilot scale, giving clean conversion but raising metal-residue questions framed by ICH Q3D.

2.3 Core Application Matrix

• Clinical chemistry and enzyme-coupled diagnostics: NADH is the consumable chromophore for ultraviolet methods measuring lactate dehydrogenase, transaminases, urea, ammonia and pyruvate. Formulators buy on lot-to-lot reproducibility of the 340 nm response and low residual absorbance at 260 nm, because either drift changes the calibration slope of finished kits.
• In-vitro biocatalysis for chiral synthesis: Ketoreductases, ene-reductases, amine dehydrogenases and P450 cascades consume NADH at industrial scale for chiral alcohols and amines. Operators of enzyme-membrane reactors need a stated reduced-form ratio and negligible contaminating NADH-oxidase activity, which otherwise silently destroys achievable turnover numbers.
• Reference material for NADome and metabolomic assays: Quantification of NAD+/NADH ratios in cell and tissue extracts relies on enzymatic cycling assays and LC-MS/MS calibration. Metrology-grade NADH, characterised under practices modelled on ISO 17034 and ISO/IEC 17025, anchors those curves.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand has shifted from quantity toward verified quality. Growth in enzymatic diagnostic panels, particularly across Asia-Pacific hospital networks, sustains steady reagent consumption, while the faster-growing segment is high-specification material for kit calibration and synthetic-biology workflows. Buyers increasingly request endotoxin and nuclease data formerly demanded only of injectable inputs. Substitution pressure also exists from NADPH systems and engineered NAD analogues.

3.2 Capacity Distribution and Export Flows

Enzymatic reduction capacity sits with nucleotide specialists rather than commodity vitamin makers. Chinese producers in Zhejiang, Jiangsu and Shandong have integrated forward from nicotinamide mononucleotide intermediate chemistry into finished coenzyme products and now anchor global research-grade volume, while Japanese and Western producers retain the documentation-heavy segment. Because reaction volumes are small and purification is chromatography-bound, capacity additions arrive slowly and need lengthy qualification before they enter export flows.

3.3 Market Bifurcation and Pricing Dynamics

Two price tiers are firmly established. Research-grade powder at ordinary purity is commodity-priced and contestable, generally trading from several hundred to a few thousand US dollars per kilogram depending on the reduced-form certificate. Material carrying low endotoxin limits, DNase/RNase-free certification, tighter water specification and full campaign documentation trades at a substantial multiple. The premium buys transferred liability: stability evidence, change control and a defensible audit trail.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Although normally regarded as a non-hazardous biochemical, exported lots face dense obligations once declared use moves from bench reagent toward a regulated product. The controlling variable is end use: nominally identical material can be a commodity research reagent, a purchased critical component of an IVD kit under Regulation (EU) 2017/746, or an input to an investigational medicinal product made under GMP. Agreements should state which applies.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH status and CLP notification: Naturally occurring and fermentation-derived substances attract registration obligations only above one tonne per year per manufacturer, importer or Only Representative. Most exporters hold a registration through their own legal entity or European representative, or deliberately stay below the threshold. Lots carry a non-classified safety data sheet, and any change to classification or salt form must be communicated under CLP before shipment.
• IVDR interface with ISO 13485 expectations: Regulation (EU) 2017/746 does not turn a bulk reagent into a device, but kit manufacturers must control purchased critical materials under their own quality system, so their suppliers are audited against ISO 13485-inspired criteria: change control, notification of process drift, retained samples and certificate traceability. Where lots enter clinical manufacture, ICH Q7 principles apply.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA listing and downstream FDA control: The substance is included on the TSCA inventory, so import is permitted subject to the usual certification at entry, and the FDA does not approve NADH as a reagent. Non-clinical research needs no filing; where material feeds a licensed product, production must conform to 21 CFR Parts 210 and 211.
• Research-use labelling and the supplement boundary: US distribution depends on unambiguous labelling. NADH has featured in new dietary ingredient notifications, creating genuine diversion risk into consumer channels. Professional suppliers therefore label lots "Research Use Only, not for human or veterinary use, not a finished consumer product" and apply documented know-your-customer screening to every new account. No health, longevity or NAD+-modulating representation accompanies the sale.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Environmental scrutiny reaches even multi-kilogram biochemicals. Because campaigns depend on preparative chromatography and lyophilisation or frozen storage, the footprint is far less benign than the volumes suggest. Buyers with Scope 3 reporting obligations increasingly request process-mass-intensity and solvent-recovery figures in annual scorecards, and this requirement now differentiates tenders in Europe and among multinational diagnostic manufacturers.

5.1 Carbon Footprint and Circular Economy

Three hotspots dominate: eluent disposal in preparative chromatography, where acetonitrile and buffer salts account for most process mass intensity; energy for lyophilisation, cold storage and frozen freight; and effluent treatment. Replacing dithionite stoichiometry with enzymatic regeneration removes most of the sulfate load and is usually the largest single improvement available to a producer. Some European buyers now expect a cradle-to-gate product carbon footprint consistent with ISO 14067.

5.2 Sustainable Sourcing and Traceability

Strain provenance is the traceability question specific to this molecule. Enzymes derived from yeasts or bacteria can carry obligations under the Nagoya Protocol and under EU Regulation 511/2014 where the source organism originates in a provider country, so importers should obtain documented proof of lawful acquisition and mutually agreed terms. Purchasers additionally require animal-derived-input declarations and TSE/BSE status, GMO status for the production strain, ISO 14001 evidence at the site, and a vendor list for contact materials and media.

VI. Supply Chain Resilience and Export Logistics

NADH disodium salt is a stable-looking powder that behaves like a perishable, and most disputes in this category are logistics rather than chemistry disputes. Sound programmes treat it as a cold-chain product with a defined excursion budget, qualify each lane seasonally, and require shared excursion data before accepting a delivery.

6.1 Packaging Standards and Moisture/Contamination Control

• Containment, headspace control and light protection: The preferred configuration is amber glass or high-barrier laminate with nitrogen headspace, sealed with desiccant inside a moisture-barrier pouch and boxed with a secondary oxygen absorber where the specification allows. Purging headspace removes the oxygen half-reaction driving NADH loss; controlling copper and iron on contact surfaces removes the accelerating pathway.
• Aliquot strategy matched to consumption: Repeated opening destroys the benefit of inert packaging, so buyers divide bulk deliveries into single-use aliquots at receipt, ideally under controlled humidity. Suppliers should offer small-format vials validated for a stated number of openings and provide an in-use stability statement rather than only a nominal expiry date.

6.2 Dangerous Goods Identification and Transit Protocols

The substance is normally not classified as dangerous for transport under UN, IMO, IMDG, ADR or IATA provisions, so the regulated component is usually the refrigerant: solid carbon dioxide is UN1845 and requires quantity declaration, marking, the applicable packing instruction and air-waybill notation. Customs declarations under HS heading 2934 for nucleic acids and their salts should stay consistent across the account, since treatment differs between research and food classifications. Shipments should move on qualified lanes with continuous temperature recording reviewed as a release condition.

VII. Enterprise Global Expansion Strategy Guide

Rational procurement starts from the recognition that the cheapest certificate is rarely the cheapest material. Programmes specifying only total purity systematically buy degraded coenzyme and absorb the cost later as failed runs and re-standardised kits. The following steps distinguish successful programmes from failing ones.

1. Specify the reduced-form ratio rather than headline purity: Write the NADH-to-NAD+ ratio into the contract as a release and retest parameter with a numerical limit, alongside water content, sodium content, metals under ICH Q3D and solvents under ICH Q3C. Insist the analytical method be named, since dithionite-derived material can satisfy an absorbance-only specification while carrying inactive adducts.
2. Qualify two suppliers under different regimes: Maintain at least one enzymatic-route producer and one alternative source in different jurisdictions, and verify every incoming lot against an independent in-house method rather than the supplier certificate. This removes single-plant risk and limits exposure when a regional supply sits inside one tariff perimeter.
3. Protect the material contractually and through vetting: Execute confidentiality agreements before tech-transfer discussion, require notification of every changed raw material, resin and strain, and run documented end-use screening on new accounts to keep supply inside the research and diagnostic perimeter. Where IVD or clinical manufacture is intended, agree the quality agreement and audit rights at the outset, not after the first deviation.

VIII. Conclusion

NADH disodium salt rewards those who understand it as a metastable reduced form rather than an inert salt. Everything decisive follows from protecting the hydride to the point of use: regeneration instead of stoichiometric reduction, chromatography resolving adducts from intact coenzyme, and packaging designed around oxygen, moisture and light exclusion. Treating this as a cold-chain service problem rather than a commodity purchase consistently lowers total cost and unexplained re-runs.

Through 2026, expect price compression in bulk research-grade material, scarcity of qualified low-endotoxin lots, and rising documentation expectations from the European IVDR environment and US research-use enforcement. This material has no approved therapeutic indication, is not offered as a finished consumer or dietary product, and carries no anti-aging, energy or NAD+-booster representation. It is a reduced coenzyme for research, diagnostic and bioprocess applications and should be specified, shipped and used on that basis.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Beta-Nicotinamide Adenine Dinucleotide, Reduced Form, Disodium Salt Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Beta-Nicotinamide Adenine Dinucleotide, Reduced Form, Disodium Salt supply chain:

• China East Coast nucleotide and coenzyme cluster: Vertically integrated producers in Zhejiang, Jiangsu and Shandong combine nicotinamide-mononucleotide chemistry with enzymatic coupling capacity, delivering cost-competitive research-grade volume. Strengths are speed of scale-up and breadth of related nucleotides; recurring limitations are audit maturity and validated export cold chain.
• European Union reagent and IVD manufacturing belt: Germany, Switzerland and the Benelux countries host diagnostic-kit formulators with their upstream suppliers, operating under ISO 13485-aligned systems. Volumes are modest and prices high, but this ecosystem sets the benchmark for endotoxin control, change notification and traceability that exporters must meet.
• Japan and Republic of Korea specialists: Established Japanese fermentation houses supply highly consistent high-purity lots with conservative, well-documented processes serving domestic diagnostic manufacturers, while Korean producers add competitive enzymatic process development. Both benchmark realised quality and act as second sources when other regions cannot meet specification.